CTOs on the Move


 
BioAmber is a renewable chemistry company. We use agricultural crops and transform them into green chemicals that directly substitute chemicals derived from oil. BioAmber combines industrial biotechnology and chemical catalysis into a process that offers a better carbon footprint than petrochemicals. In addition to moving away from petroleum, our process consumes CO2, directly reducing greenhouse gas emissions and aiding in the fight against global warming. Bioamber is today the only producer of bio-succinic acid, a chemical building block used in a number of applications, such as plastics, polyurethane, solvents, personal care, plasticisers, etc.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.bio-amber.com
  • 1250 Rene-Levesque Blvd. West Suite 4110
    Montreal, QC CAN H3B 4W8
  • Phone: 514.844.8000

Executives

Name Title Contact Details

Similar Companies

Florida Hospital Orlando

Florida Hospital Orlando is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Minute Molecular Diagnostics

Minute Molecular Diagnostics was founded in 2017 as a spinout of the Northwestern University Center for Innovation in Global Health Technology (CIGHT). Comprised of a strong management team with extensive diagnostic industry experience, the company has raised $8 million in funding from the NIH and Diagnostic Industry Executives.

Enthalpy Analytical

Enthalpy Analytical, Inc. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novartis Consumer Health Inc

Novartis Consumer Health Inc is a Big Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevation Oncology

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor`s unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.